DENALI THERAPEUTICS INC (DNLI)
NASDAQ • Healthcare
$24.31
-$0.04 (-0.2%)
Market open
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About DENALI THERAPEUTICS INC
Name
DENALI THERAPEUTICS INC
CEO
Ryan J. Watts
Website
Industry
Healthcare
Year Founded
2013
Employees
503
Denali Therapeutics Inc. is a U.S.-focused biotechnology company listed on NASDAQ as DNLI that develops drug candidates for neurodegenerative and related diseases. In qualitative terms, it is a clinical-stage healthcare business built around advancing targeted therapies, with programs that span Parkinson's disease, ALS, Hunter syndrome, multiple sclerosis, Alzheimer's disease, and cutaneous lupus erythematosus.
Fundamentals & Financials
Revenue (TTM)
$3.6M
Net Income (TTM)
-$511.4M
EPS (TTM)
-$2.84
ROA (TTM)
-44.17%
Current Ratio
8.37
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Stay Ahead of the Market
Get premium market insights delivered directly to your inbox.
Quote Summary
Previous CloseDay Range$24.31$24.01 - $24.49
52 Week RangeAvg. Volume$12.58 - $27.31.3M
Market Cap$3.9B
Peers & Related Assets
IBRXIMMUNITYBIO INC
$7.72-2.5%
LQDALIQUIDIA CORP
$74.33-4.3%
COGTCOGENT BIOSCIENCES INC
$37.4-1.2%
RCUSARCUS BIOSCIENCES INC
$29.51-0.2%
BEAMBEAM THERAPEUTICS INC
$26.57-2.0%
VRDNVIRIDIAN THERAPEUTICS ORS INC
ETNB89bio, Inc.
AGIOAGIOS PHARMACEUTICALS INC
GLPGGalapagos N.V.
RXRXRECURSION PHARMACEUTICALS INC CLAS